VivoSeq
Psychiatry

Bipolar I Disorder

53

Pipeline Programs↗

7

Active Trials↗

27

Companies Involved↗

Bipolar I Disorder is a moderately active landscape with 53 programs across 27 companies. The most active players are Merck & Co., Eli Lilly, Sumitomo Pharma America, Inc.. 6 therapies are approved with 26 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

11/100

Mech. Concentration

12/100

Completion Rate

84/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 2Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

1 program

Phase 2Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 2M

Memory Pharmaceuticals

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

94

clinical trials

Completed72 · 77%
Terminated10 · 11%
Recruiting5 · 5%
Withdrawn3 · 3%
Suspended1 · 1%
Active, not recruiting1 · 1%
Other2 · 2%

Clinical Trials

Trial Activity

94 trials

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Recruiting·AAlkermes, Inc.·Phase 3·NCT05303064·220 enrolled
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Recruiting·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 2·NCT07288320·150 enrolled
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
Recruiting·—·Phase 2·NCT05977023·90 enrolled
A Phase 2, Multicenter, 6-Week, Double Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Bipolar Depression
Recruiting·AbbVie logoAbbVie·Phase 2·NCT06696755·195 enrolled
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Magnesium Vitamin B6 in Combination With Treatment as Usual in First Episode of Bipolar I Disorder
Recruiting·MMclean Hospital·Phase 2·NCT05837104·40 enrolled
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Active, not recruiting·JJina Pharmaceuticals Inc.·Phase 3·NCT06608641·490 enrolled
Open Label Extension Study of NCT06221852 of the Ketogenic Diet in Participants With First Episode Bipolar Disorder.
Enrolling by invitation·MMclean Hospital·Preclinical·NCT06558201·50 enrolled
Lurasidone and Cognition in Bipolar I Disorder
Completed·UUniversity of British Columbia·Phase 3·NCT02147379·53 enrolled
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00107731·710 enrolled
A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00035230·338 enrolled
An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients
Completed·GSK logoGSK·Phase 3·NCT00550407·215 enrolled
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
Completed·Novartis logoNovartis·Phase 4·NCT00139594·181 enrolled
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00081380·710 enrolled
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00257075·267 enrolled
A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00037674·434 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)